Skip to main content
. 2022 Dec 3;14(23):5985. doi: 10.3390/cancers14235985

Figure 2.

Figure 2

Baseline serum IL-6 levels and survival outcome with pembrolizumab/axitinib therapy. (a) Comparison of IL-6 levels according to the best response. Values were compared using ANOVA with Tukey’s post hoc test with respective p-values given in each plot. (b) Time-dependent receiver operator characteristic curve of serum IL-6 levels. (c) Bar charts showing the best response to therapy by IL-6 level.